BIOPTIC B1 Ultra-High-Throughput Virtual Screening System Discovers LRRK2 Ligands in Vast Chemical Space

The rapid expansion of chemical space presents significant
challenges
in identifying novel ligands for drug targets. Here, we introduce
BIOPTIC B1, an ultra-high-throughput ligand-based virtual screening
system capable of rapidly evaluating multi-billion-molecule libraries
in minutes. In retrospective analyses across seven diverse drug targets,
BIOPTIC B1 demonstrated performance comparable to state-of-the-art
machine learning models, including Chemprop and Gradient Boosting.
Prospectively, we applied BIOPTIC B1 to leucine-rich repeat kinase
2 (LRRK2), a high-priority drug target for Parkinson’s disease.
BIOPTIC B1 successfully identified multiple novel ligands binding
both wild-type and G2019S-mutant LRRK2 with dissociation constants
(Kd) as low as 110 nM, directly from the Enamine REAL Space
of 40 billion molecules. These findings highlight BIOPTIC B1 as a
powerful tool for novel hit identification and scaffold hopping within
ultra-large chemical space, offering significant advancements in virtual
screening for drug discovery.